Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Pre-operative Panitumumab, Paclitaxel, Carboplatin and Continuous Infusion 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma

NCT01182610 is registered in ClinicalTrials.gov with Accelerated Community Oncology Research Network as lead sponsor.

NCT NCT01182610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01182610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Pre-operative Panitumumab, Paclitaxel, Carboplatin and Continuous Infusion 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma
Lead sponsor
Accelerated Community Oncology Research Network
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2011
Completion date
March 31, 2012
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the distal esophagus, adenocarcinoma of the proximal stomach, adenocarcinomas of the gastroesophageal junction, gastroesophageal adenocarcinoma